Thrombocytopénie Purpura Thrombotique Acquise (ATTP)
Articles
Real-World Insights on Managing Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications.
Caplacizumab is an innovative nanobody® and cornerstone in the treatment of iTTP.1 This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.2
When to suspect TTP?
TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.
What is TTP? A rare, life-threatening medical emergency
Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.
.webp/jcr:content/ISTH%20logo-cover%20image%20(1).webp){kind=logo}
Lignes directrices de l'ISTH : Les premières ‘evidence-based’ lignes directrices pour le PTT
Les contenus accessibles par ce site sont destinés exclusivement aux Professionnels de Santé.
Les contenus accessibles par ce site sont destinés
exclusivement aux Professionnels de Santé.
Sanofi met a votre disposition, sur un portail unique dédié aux professionnels de santé, des contenus exclusifs comprenant des contenus scientifiques et des outils pour votre pratique quotidienne.